The study was designed to define the contribution of cytochrome p450 2C19 (CYP2C19) and cytochrome p450 3A4 (CYP3A4) to citalopram N-demethylation and to evaluate the relationship between the disposition of citalopram and CYP2C19 genotype. A single oral 40-mg dose of citalopram was administered to eight extensive metabolizers and five poor metabolizers recruited from 77 healthy Chinese voluntee...

background: this study was designed to investigate the eff ect of clopidogrel-related gene polymorphisms on platelet reactivity and clinical outcome in chinese han patients. materials and methods: th ree hundred and thirty-six percutaneous coronary intervention - treated patients were recruited and followed for 1 year. blood samples were collected from all patients for dna genotyping. th e plat...

According to recommendations of ESC 2020-year, de-escalation therapy with a P2Y12 receptor inhibitor (transition from prasugrel or ticagrelor clopidogrel) It can be considered as an alternative strategy dual antiplatelet (DAPT) for patients acute coronary syndrome (ACS) who are unsuitable the use strong platelet inhibitor. De-escalation performed based on individual clinical evaluation under su...

Background: Cytochrome P450 2C19 (CYP2C19) is a polymorphically expressed enzyme that shows marked interindividual and interethnic variation. CYP2C19*2 and CYP2C19*3 are the most frequently identified defective alleles in Orientals and Caucasian poor metabolizers (PM). The aim of this study was to investigate the frequencies of CYP2C19*1, CYP2C19*2 and CYP2C19*3 alleles and CYP2C19 genotypes in...

background: clopidogrel is one of the most commonly prescribed drugs to prevent ischemic events following coronary syndromes or stent placement. however, impaired responses to therapy as well as resistance are also reported. genetic variants play an important role in clopidogrel biotransformation to its active metabolite that may subsequently influence the clopidogrel antiplatelet effect. the o...

Clopidogrel resistance from CYP2C19 polymorphism has been associated with stent thrombosis in patients undergoing percutaneous coronary intervention with drug-eluting stents. We present a case of a 76-year-old male who received drug-eluting stents to the right coronary artery and left anterior descending artery for non-ST elevation myocardial infarction and was discharged on dual antiplatelet t...

Escitalopram and sertraline are among the most widely used drugs in the treatment of depression in Norway. Both drugs show substantial pharmacokinetic variability. Previous studies have indicated that the drug metabolising enzyme cytochrome P450 2C19 (CYP2C19), which exhibits extensive variability in activity due to genetic polymorphism, is involved in the metabolism of escitalopram and sertral...

In this study, CYP2C19 genotypes were tested by the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method in 92 patients with multiple myeloma (MM). Sixty-two patients were treated with thalidomide plus dexamethasone (Thal+Dex) and 30 with thalidomide combined with chemotherapy (Thal+CC). The overall response rate of extensive metabolizers (EMs) was statistically ...

The capacity of clopidogrel to inhibit ADP-induced platelet aggregation shows wide intersubject variability. To determine whether frequent functional variants of genes coding for candidate cytochrome P450 (CYP) isoenzymes involved in clopidogrel metabolic activation (CYP2C19*2, CYP2B6*5, CYP1A2*1F, and CYP3A5*3 variants) influence the platelet responsiveness to clopidogrel, we conducted a prosp...